See more : Braime Group PLC (BMT.L) Income Statement Analysis – Financial Results
Complete financial analysis of Intelligent Bio Solutions Inc. (INBS) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Intelligent Bio Solutions Inc., a leading company in the Medical – Diagnostics & Research industry within the Healthcare sector.
- Henderson High Income Trust plc (HHI.L) Income Statement Analysis – Financial Results
- Condor Technologies NV (MLMFI.PA) Income Statement Analysis – Financial Results
- Signature Bank (SBNY) Income Statement Analysis – Financial Results
- SILK Laser Australia Limited (SLA.AX) Income Statement Analysis – Financial Results
- MSA Safety Incorporated (MSA) Income Statement Analysis – Financial Results
Intelligent Bio Solutions Inc. (INBS)
About Intelligent Bio Solutions Inc.
Intelligent Bio Solutions Inc., a life sciences company, developing non-invasive, real-time monitoring and diagnostic tests for patients and their primary health practitioners. It offers Saliva Glucose Biosensor, an organic thin-film transistor for diabetes management that measures glucose in saliva. The company also focuses on developing SARS-CoV-2 Biosensor, a biosensor test can be used as a complement to the (RNA) virus detection test; and a biosensor platform comprising of biochemistry, immunology, tumor markers, hormones, and nucleic acid diagnostic modalities. The company was formerly known as GBS Inc. and changed its name to Intelligent Bio Solutions Inc. in October 2022. The company was incorporated in 2016 and is headquartered in New York, New York. Intelligent Bio Solutions Inc. is a subsidiary of Life Science Biosensor Diagnostics Pty Ltd.
Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
---|---|---|---|---|---|---|---|---|
Revenue | 3.11M | 1.26M | 0.00 | 1.98M | 188.74K | 0.00 | 0.00 | 0.00 |
Cost of Revenue | 1.69M | 930.20K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | 1.43M | 326.67K | 0.00 | 1.98M | 188.74K | 0.00 | 0.00 | 0.00 |
Gross Profit Ratio | 45.81% | 25.99% | 0.00% | 100.00% | 100.00% | 0.00% | 0.00% | 0.00% |
Research & Development | 1.67M | 507.42K | 3.85M | 4.27M | 588.21K | 3.18M | 2.53M | 0.00 |
General & Administrative | 0.00 | 0.00 | 4.92M | 3.71M | 2.43M | 3.55M | 2.08M | 139.10K |
Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 33.90K |
SG&A | 9.26M | 8.03M | 4.92M | 3.71M | 2.43M | 3.55M | 2.08M | 173.00K |
Other Expenses | 776.50K | 0.00 | -437.15K | -947.41K | -188.74K | 0.00 | 0.00 | 0.00 |
Operating Expenses | 11.71M | 8.76M | 8.34M | 7.03M | 2.83M | 6.73M | 4.60M | 173.00K |
Cost & Expenses | 13.39M | 9.69M | 8.34M | 7.03M | 2.83M | 6.73M | 4.60M | 173.00K |
Interest Income | 84.82K | 9.68K | 14.43K | 13.81K | 97.00 | 188.00 | 564.00 | 151.28K |
Interest Expense | 167.14K | 223.53K | 7.54K | 1.09M | 457.75K | 664.84K | 453.87K | 0.00 |
Depreciation & Amortization | 1.20M | 966.73K | 8.34M | 5.21M | 2.60M | 5.83M | 4.60M | 188.72K |
EBITDA | -8.81M | -9.47M | 30.83K | -1.82M | -561.19K | -1.50M | -416.92K | -151.28K |
EBITDA Ratio | -283.14% | -593.55% | 0.00% | -361.23% | -1,433.70% | 0.00% | 0.00% | 0.00% |
Operating Income | -10.28M | -12.60M | -8.34M | -5.57M | -2.71M | -6.73M | -4.60M | -173.00K |
Operating Income Ratio | -330.46% | -1,002.11% | 0.00% | -281.42% | -1,433.70% | 0.00% | 0.00% | 0.00% |
Total Other Income/Expenses | 92.24K | 1.93M | 2.90K | -1.71M | -457.75K | -664.84K | -453.31K | -138.67K |
Income Before Tax | -10.19M | -10.66M | -8.33M | -8.52M | -3.16M | -7.39M | -5.06M | -311.67K |
Income Before Tax Ratio | -327.50% | -848.50% | 0.00% | -430.15% | -1,676.23% | 0.00% | 0.00% | 0.00% |
Income Tax Expense | 0.00 | 190.70K | -27.93K | 2.50M | 550.26K | -57.69K | -36.39K | -167.01K |
Net Income | -10.16M | -10.63M | -8.31M | -7.04M | -3.16M | -7.34M | -5.02M | -340.01K |
Net Income Ratio | -326.40% | -845.89% | 0.00% | -355.33% | -1,676.23% | 0.00% | 0.00% | 0.00% |
EPS | -6.38 | -10.58 | -11.33 | -16.22 | -8.92 | -21.01 | -14.60 | -0.99 |
EPS Diluted | -6.38 | -10.58 | -11.33 | -16.22 | -8.92 | -21.01 | -14.60 | -0.99 |
Weighted Avg Shares Out | 1.59M | 1.00M | 733.26K | 433.95K | 354.60K | 349.28K | 343.75K | 343.75K |
Weighted Avg Shares Out (Dil) | 1.59M | 1.00M | 733.26K | 433.95K | 354.60K | 349.28K | 343.75K | 343.75K |
Intelligent Bio Solutions Inc. to Present at the Emerging Growth Conference on December 7, 2023
Australian Civil Construction Entity, State Road Constructions, Selects Intelligent Fingerprinting Drug Screening System as Workplace Drug Screening Solution
Why Is Intelligent Bio Solutions (INBS) Stock Up 56% Today?
Intelligent Bio Solutions Inc. Reports Fiscal 2024 First Quarter Financial Results and Operational Highlights
Intelligent Bio Solutions' Innovative Drug Screening Technology Now Offered in New Zealand
Intelligent Bio Solutions Adds Logistics Firm to Fingerprint Drug Screening Portfolio and Completes Major Milestone with Existing Client
Intelligent Bio Solutions Inc. Announces Closing of $4.378 Million Underwritten Public Offering Including Partial Exercise of Underwriters' Overallotment Option
Why Is Intelligent Bio Solutions (INBS) Stock Down 52% Today?
Intelligent Bio Solutions Inc. Announces Pricing of $4,000,000 Underwritten Public Offering
Intelligent Bio Solutions Obtains ISO Recertification for its Intelligent Fingerprinting Drug Screening Business
Source: https://incomestatements.info
Category: Stock Reports